Valganciclovir
Valganciclovir is an orally active antiviral agent. Valganciclovir can inhibit the growth of adenoviruses and have a protective effect on immunosuppressed hamsters. Valganciclovir can be used for the research of Cytomegalovirus.
For research use only. We do not sell to patients.
- CAS No.: 175865-60-8
- Formula: C14H22N6O5
- Molecular Weight:354.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Valganciclovir (500 μM, 5-7 days) inhibits the growth of human adenoviruses (Ads) in A549 cells[1].
Valganciclovir (0.003-10 mM, 10 min) with ganciclovir (HY-13637) inhibits the uptake of glycylsarcosine in Caco-2 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells
-
Concentration:500 μM
-
Incubation Time:5 days, 7days
-
Result:Showed EC50 values ranged from 120.5 μM (Ad4) to 244.4 μM (Ad6). Showed IC50 values was calculated to be 11.74 mM at 7 days post-infection.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immunosuppressed hamsters[1]
-
Dosage:200 mg/kg
-
Administration:Oral gavage (p.o.)
-
Result:Resulted in significantly smaller magnitude of weight loss for all groups.
Reduced the liver pathology.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 175865-60-8
-
Molecular Weight 354.36
-
Formula C14H22N6O5
-
SMILES
N[C@@H](C(C)C)C(OCC(OCN1C=NC2=C1N=C(N)NC2=O)CO)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Toth K, et al. Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters [J]. Viruses, 2015, 7(3): 1409-1428. [Content Brief]
[2]. Sugawara M, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9. [Content Brief]
[3]. Cvetkovic R S, et al. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients [J]. Drugs, 2005, 65: 859-878. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz